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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of non-contact screening methods for identifying eyes with a narrow angle.
B A C K G R O U N D
Clinical problem
Primary angle closure (PAC) is characterised by appositional or
adhesional (synechial) narrowing (and eventually occlusion) of the
drainage angle in the anterior chamber of the eye, resulting in el-
evated intraocular pressure (IOP) and subsequent glaucomatous
optic neuropathy, a condition known as primary angle closure
glaucoma (PACG). The occlusion of the drainage angle may oc-
cur rapidly or slowly. Rapid occlusion results in symptomatic IOP
elevation that requires emergency medical treatment (known as
acute angle closure). Individuals presenting with acute angle clo-
sure, characterised by eye pain, headache, corneal oedema and vas-
cular congestion, are treated initially with topical and oral medi-
cations to lower the IOP. This is followed by laser peripheral irido-
tomy as soon as possible after angle closure, usually with prophy-
lactic treatment of the fellow eye (Emanuel 2014). An occlusion
that develops insidiously results in chronically raised IOP, which
is often asymptomatic. Management for chronic angle closure in-
volves: medical (topical hypotensives); laser peripheral iridotomy;
filtration surgery or a combination of these to lower the IOP and
open up the drainage angle. A recently published multicentred
randomised controlled trial has provided evidence that clear lens
extraction is associated with better clinical and patient-reported
outcomes than peripheral iridotomy and may therefore be a better
first-line treatment option (Azuara-Blanco 2016).
A recent systematic review found the global prevalence of PACG
to be 0.5% of individuals aged 40 to 80 years, and estimated that
the number of people with the disease will reach 23.4 million
by 2020 and 32 million by 2040 (Tham 2014). Although, glob-
ally, open-angle glaucoma is more common (3%) (Tham 2014),
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PACG is more likely to result in bilateral blindness (Quigley 1996;
Resnikoff 2004). PACG accounts for approximately 50% of glau-
coma blindness, and it has been estimated that by 2020, 5.3 mil-
lion people worldwide will be bilaterally blind (Quigley 2006).
A classification scheme for PAC designed for use in prevalence
surveys and epidemiological research has been published by Foster
and colleagues (Foster 2002). This identifies three stages in the
natural history of angle closure from initial irido-trabecular contact
(ITC) to anterior segment signs of disease (raised IOP, peripheral
anterior synechiae (PAS), or both), culminating in glaucomatous
optic neuropathy.
1. PAC suspect (PACS): an eye in which appositional contact
between the peripheral iris and posterior trabecular meshwork is
considered in two or more quadrants, in dark room conditions
using static gonioscopy,
2. PAC: an eye with an occludable drainage angle and features
indicating that trabecular obstruction by the peripheral iris has
occurred, such as PAS, elevated IOP (> 21 mmHg), iris whorling
(distortion of the radially orientated iris fibres), “glaucomfleken”
lens opacities or excessive pigment deposition on the trabecular
surface. There is no evidence of glaucomatous optic neuropathy
or associated glaucomatous field loss.
3. PAC glaucoma (PACG): signs of PAC, as described above,
and evidence of glaucomatous optic neuropathy.
It has been estimated that the proportion of PACS that converts to
PAC ranges from 10% to 40% per decade (Alsbirk 1992; Thomas
2003; Yip 2008), and the five year risk of progression from PAC
to PACG has been reported to be 28% to 30% (Thomas 2003;
Wilensky 1993).
There are various anatomical anddemographic risk factors for PAC
(Congdon 1996; Lowe 1970). Anatomical risk factors include: a
shallow anterior chamber depth (ACD), thickening of the crys-
talline lens, small corneal diameter and a short axial length (Nolan
2006). The risk of PACG increases with age (Day 2012) and the
prevalence also varies with ethnicity, with higher rates occurring
in Inuit and Asian populations (Clemmesen 1971; Drance 1973;
Tham 2014).
Target condition being diagnosed
For this review we will use a narrow angle as the target condition
indicative of an anatomical predisposition to angle closure as iden-
tified by gonioscopy (Weinreb 2006). In this review we define a
narrow angle as either:
• an eye which has appositional contact between the
peripheral iris and posterior trabecular meshwork in two or more
quadrants (≥180°); or
• an eye with or at risk of angle closure as judged by a trained
and experienced eye care professional using gonioscopy with or
without indentation.
Conditions that are similar to the target condition include sec-
ondary angle closure glaucoma, such as aqueousmisdirection, neo-
vascular glaucoma and ciliary body swelling. The clinical features
and management of conditions that cause secondary angle closure
glaucoma have been reviewed by Parivadhini 2014 and will not be
investigated in this review.
Index test(s)
Targeted screening for PAC/PACG has established the effective-
ness of measuring anterior chamber dimensions to identify oc-
cludable angles (Congdon 1996; Devereux 2000; Kurita 2009). A
variety of non-contact methods are available for the assessment of
the ACD, anterior chamber angle (ACA), or both.
Flashlight/pen torch/oblique handlight technique
The flashlight test is an accessible screening method if no other
equipment is available. The test can be carried out in a primary-
or secondary-care setting and involves shining a pen torch into
the eye from the temporal limbus parallel to the iris to assess the
ACD. Quantitative grading uses a four-point scale, derived from
how much the iris is illuminated by the light of the pen torch
(grade 4 = iris is fully illuminated; grade 1 = less than one-third of
the iris is illuminated) (Van Herick 1969; Vargas 1973)); grade 1
is associated with a high risk of angle closure. Qualitative grading
can be used to describe the amount of shadow falling on the iris
as shallow, medium or deep, and is further described by He 2007.
Limbal anterior chamber depth assessment (van
Herick technique)
The van Herick technique is used to assess the ACD at the limbus
using a slit lamp biomicroscope (Van Herick 1969). The illumi-
nation system is set at 60° from the observation system. A focused
vertical slit-beam is positioned at the limbus and moved just onto
the cornea until the beam separates into a corneal section and re-
flection of the beam onto the iris. An estimate of the thickness
of the dark space between the beams (which corresponds to the
limbal anterior chamber depth (LACD)) is recorded as a fraction
(or percentage) of the corneal section thickness over the central
portion of the beam. Van Herick 1969 originally described a four-
point grading scheme, which was extended to a seven-point scale
by Foster 2000. Foster 2000 used an intuitive percentage scale,
in an effort to improve the precision of the measurement. Van
Herick 1969 considered that an eye with a LACD of grade 2 or
less required gonioscopy and that a grade 1 angle was at a high
risk of angle closure. Foster 2000 further subdivided grade 1 into
5% and 15% cut-off values and found that the augmented scale
was associated with an improved test accuracy.
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Scanning peripheral anterior chamber depth analysis
Scanning peripheral anterior chamber depth analysis (SPAC) is an
objectivemethod formeasuring the peripheral and central ACDby
automatically taking 21 slit lamp images of the anterior chamber
using a 1 mm-wide slit at 0.4-mm intervals from the optical axis
towards the limbus (Kashiwagi 2006). These measurements are
compared to a normative database and converted into a numerical
scale ranging from 1 to 12, with 12 representing the deepest ACD.
In addition, the instrument provides a categorical grading of the
risk of angle closure, with suspect angle closure indicated by ≥
4 measured points exceeding the 95% confidence interval (CI),
potential angle closure indicated by≥ 4 points exceeding the 72%
CI, and normal. The device has been shown to be reproducible
and easy to operate, therefore making it suitable for use by non-
clinicians (Kashiwagi 2004).
Scheimpflug photography
The Scheimpflug principle is used to correct perspective distor-
tion in aerial photographs and has been adapted for ocular imag-
ing. The Oculus Pentacam (Oculus, Wetzlar, Germany) device
employs this principle using monochromatic blue light at a wave-
length of 475 nm. By rotating the apparatus around the optical
axis of the eye, a series of radially oriented images is generated in
three dimensions around the 360° extent of the anterior segment.
Between 12 and 50 real-time sections from the anterior surface of
the cornea to the posterior vertex of the lens are acquired within
a 2-s acquisition frame. This generates a set of measurements that
provide a detailed description of the biometric configuration of the
anterior segment, which includes the ACA, ACD and the anterior
chamber volume (ACV). When calculating the ACA, it should
be noted that this is not a direct measurement of the ACA, but
is extrapolated from the measurements taken by the Pentacam.
Some studies have found the ACD to be an effective indicator for
the detection of narrow angles using various cut-off ACD values
(2.6 mm, 1.93 mm, 2.27 mm) (Hong 2009; Kurita 2009; Rossi
2012). Another study found ACV to partition normal eyes from
those at risk of angle closure (Grewal 2011). Currently there is
no consensus on which parameter or cut-off value to use in the
determination of a narrow angle.
Anterior segment-ocular coherence tomography
Anterior segment-ocular coherence tomography (AS-OCT) allows
both qualitative and quantitative analysis of the angle. The tech-
nique is based on low-coherence interferometry whereby the delay
and intensity of light reflected from the ocular tissue structures
is measured. There are currently several AS-OCT devices avail-
able on the market; depending on the device, they use one of the
following methods to obtain clinical data: time domain, spectral
domain or the more recent swept source domain method. Spectral
and swept source domain methods have a higher scan speed and
resolution than time domain methods. A wavelength of 1310 nm
is used to image the anterior segment and inbuilt software is used
to quantitatively assess in detail angle parameters, which include:
the trabeculo-iris space area (TISA), angle recess area (ARA) and
angle opening distance (AOD) (Quek 2011). Qualitative inter-
pretation has been typically defined by contact between the pe-
ripheral iris and any part of the angle wall anterior to the scleral
spur. Studies state different AODs of 500 or 750 microns in the
detection or diagnosis of narrow angles or an ARA of less than
20° (Smith 2013). There is no current consensus on which values
to use with any of the parameters mentioned to identify a narrow
angle.
Clinical pathway
A variety of non-contact devices with varying degrees of sophis-
tication have been developed to evaluate the risk of angle closure
. The high prevalence of PAC and the burden of blindness at-
tributable to PACG in high-risk populations open up the possibil-
ity of using such techniques for population screening (see Figure
1) (Nolan 2003; Nolan 2006). More commonly, non-invasive as-
sessment of the dimensions of the ACD, angle, or both are part of
a standard ophthalmic examination in individuals who are asymp-
tomatic or those presenting with symptoms of angle closure. If the
index test(s) is positive, such individuals are identified as being ’at
risk’ of PACG and are referred for further assessment, usually to
a glaucoma subspecialist ophthalmologist. The ophthalmologist
will carry out gonioscopy (the reference standard for qualitative
and quantitative assessment of the ACA). If a narrow angle is diag-
nosed, additional tests are then performed, such as IOP measure-
ment using Goldmann applanation tonometry, optic nerve head
examination and automated threshold visual field testing, to fur-
ther diagnose the narrow angle as PACS/PAC/PACG. Depend-
ing on the clinical presentation, the affected individual may be
closely monitored or undergo prophylactic treatment with laser
iridotomy or lens extraction, possibly in conjunction with IOP-
lowering eye drops.
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Figure 1. Clinical Pathway
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Role of index test(s)
The gold standard test to detect a narrow angle is gonioscopy;
however, this is not routinely performed outside the specialist set-
ting since it requires a high level of skill, which may lead to missed
diagnoses. Non-contact screening tests are relatively quick and can
be carried out by appropriately trained healthcare professionals or
technicians as a triage test to identify eyes at risk of angle clo-
sure. These non-contact tests cannot replace gonioscopy as they do
not provide sufficient information on the ACA anatomy (Smith
2013). It should be noted that in some cases, when gonioscopy
fails to visualise the anterior chamber configuration and depth,
typically in secondary causes of angle closure, AS-OCT and Pen-
tacam imaging can be used to provide objective measurements
(Kang 2013). In addition, AS-OCT and Pentacam imaging can be
used to supplement existing clinical documentation by providing
objective measurements (Smith 2013).
Alternative test(s)
Tests that use contact methods, such as ultrasound biomicroscopy,
have been reviewed by Smith 2013, and will not be included in
the current review.
Rationale
A systematic review published in 2013 evaluated whether anterior
segment imaging (using ultrasound biomicroscopy, ocular coher-
ence tomography (OCT), Scheimpflug photography or SPAC)
aided the diagnosis of PAC (Smith 2013). This review included
79 studies and concluded that although anterior segment imaging
provided useful information, none of the methods provided suffi-
cient information about the anatomy of ACA to be considered a
substitute for gonioscopy. However, no meta-analysis of accuracy
data was conducted. The current review will update and extend
this review by considering the following non-contact methods of
anterior chamber assessment (flashlight test, slit-lamp techniques
for limbal and central ACD assessment, AS-OCT, Scheimpflug
photography and SPAC).
O B J E C T I V E S
To determine the diagnostic accuracy of non-contact screening
methods for identifying eyes with a narrow angle.
Secondary objectives
1. To asssess and compare the accuracy of index non-contact
screening tests for identifying eyes with a narrow angle
2. To investigate the accuracy of each non-contact screening
method for detecting the most severe referable condition or
PACG (versus PAC, PACS or a non-occludable angle)
3. To explore potential causes of heterogeneity in diagnostic
performance
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all prospective and retrospective cohort studies
(’single-gate’ design) and case-control studies (’two-gate’ design)
that have evaluated the accuracy of non-contact methods for di-
agnosing narrow angles compared to a gonioscopy reference stan-
dard. We will include studies comparing each method separately,
and studies comparing more than one method, to the reference
standard in the same population. This will include studies inwhich
participants receive all the tests or are randomised to receive dif-
ferent tests. We will include only studies that provide sufficient
data to allow the calculation of sensitivity and specificity.
Non-contact methods for the detection of narrow angles are
mainly of interest in screening and primary-care settings as a triage
test aiming to guide referrals to ophthalmologists. However, since
the relative accuracy of these tests in these settings is not well
known, we will include studies investigating these tests in any set-
ting, and will assess the effect of this on accuracy in subgroup
analyses.
Participants
Wewill include all participants who meet the inclusion criteria for
studies conducted in any setting (including population screening,
and primary or secondary care), which evaluated any of the index
tests against the reference standard.
Index tests
We will assess non-contact methods including: the flashlight/pen
torch/oblique handlight technique, LACD using the van Herick
technique, SPAC, Scheimpflug photography and AS-OCT.
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Target conditions
A narrow angle, as a referable condition that can include PACS,
PAC or PACG, as described above, will be the target condition of
interest.
As a secondary objective, we will also extract data to investigate
the accuracy of the test for detecting the most severe referable
condition or PACG (versus PAC, PACS or non-occludable angle).
Reference standards
Gonioscopy will be the reference standard for the diagnosis of a
narrow angle. We will further classify a narrow angle into one of
three subgroups PACS, PAC, PACG, if the following measure-
ments have been taken; IOP measurement, visual field assessment
and optic disc examination.
Gonioscopy
Gonioscopy is the acknowledged reference standard for the evalu-
ation of eyes with and at risk of angle closure, and should be per-
formed on both eyes in any individual with suspected angle clo-
sure. The technique should be performed under dark-room con-
ditions and used in the primary position to visualise angle struc-
tures, the presence of ITC, PAS, or both (Bhargava 1973). Dy-
namic assessment is helpful in distinguishing ITC from PAS using
a four-mirror lens, which is applied to the cornea creating pressure
with the goniolens. The Shaffer grading system, which records the
ACA width in four quadrants, from grade 0 (closed) to grade 4
(wide open), is themost widely adoptedACA classification scheme
(Shaffer 1960). Angle morphology can be further described using
the Scheie grading system (Scheie 1957). This scheme describes
the angle according to the anatomical structures observed (grade
IV: Schwalbe’s line not visible; grade III: Schwalbe’s line visible;
grade II: anterior trabecular meshwork visible; grade I: visible scle-
ral spur; and grade 0: ciliary body band visible).
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases. We will impose no language or
publication year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL; latest issue) (which contains the Cochrane Eyes and
Vision Trials Register) in the Cochrane Library (Appendix 1);
• Health Technology Assessment Database (HTAD; latest
issue) in the Cochrane Library (Appendix 1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• BIOSIS (January 1969 to present) (Appendix 4);
• System for Information on Grey Literature in Europe
(OpenGrey) (1995 to present) (Appendix 5);
• Aggressive Research Intelligence Facility database (ARIF) (
www.birmingham.ac.uk/research/activity/mds/projects/HaPS/
PHEB/ARIF/index.aspx) (Appendix 6);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch)
(Appendix 7);
• US National Institutes of Health Ongoing Trials Register -
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 8);
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/ictrp) (Appendix 9).
Searching other resources
We will search the references of included studies for information
about further studies. We do not intend to handsearch journals
and conference proceedings.
Data collection and analysis
Selection of studies
Two review authors (AJ and IC) will independently assess the titles
and abstracts of all studies identified by the electronic searches.We
will label each record at this stage as “definitely relevant”, “possibly
relevant” or “definitely not relevant”. We will exclude records la-
belled as “definitely not relevant” by both review authors. We will
retrieve full-text reports of records labelled as “definitely relevant”
or “possibly relevant” and the two review authors will indepen-
dently assess whether these meet the inclusion criteria. We will
resolve any disagreement when present at any stage through dis-
cussion. When necessary, we will consult a third review author or
contact the study investigators for more information to determine
eligibility.
Data extraction and management
Two review authors (AJ and JL) will independently extract the fol-
lowing data, where possible, from the included studies: the num-
ber of true positives (TP), false positives (FP), true negatives (TN)
and false negatives (FN) using 2 x 2 contingency tables. From the
2 X 2 tables we will calculate sensitivity (the proportion of dis-
eased people correctly diagnosed) and specificity (the proportion
of non-diseased people correctly diagnosed) with 95% CIs.
One review authorwill enter data intoReviewManager 5 (RevMan
5) (Review Manager 2014) and a second review author will verify
the entered data.We will resolve any disagreement when present at
any stage through discussion. We will contact study investigators
to providemissing information or to clarify data, and we will allow
twoweeks for a response. If we do not receive a response during this
time, we will proceed using the information available, as provided
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in the published reports. We will summarise the characteristics of
included studies in a ’Characteristics of included studies’ table, as
shown below. See Appendix 10 for abbreviations.
Study identification First author, year of publication.
Clinical features and settings Previous testing and clinical setting including country where the study was conducted. Presentation
at recruitment, prior treatment that would affect the ACD (i.e. peripheral iridotomy, iridoplasty,
etc.)
Participants Sample size, age, sex, ethnicity and country
Study design Whether the sample was selected as a single group (consecutive series) or as separate groups with
and without the target condition (case-control). Whether participants were consecutively enrolled
in the study and were identified retrospectively or prospectively. Training involved for index tests,
both eyes included in the study
Target condition A narrow angle as a referable condition, which includes PACS, PAC and PACG
Reference standard The reference standard test used: gonioscopy for diagnosing a narrow angle; this is acceptable if this
is the only target condition in large-scale screening or primary-care settings. Gonioscopy combined
with tonometry, visual fields investigation and optic disc assessment for distinguishing the relative
subgroup of participants with a narrow angle PACS/PAC/PACG
Index tests Flashlight/pen torch/oblique handlight technique: grade recorded
LACD using the van Herick technique: van Herick grade, or percentage, or both
SPAC: numerical or categorical grade, or both
Pentacam Scheimpflug photography: ACA, ACV and ACD
AS-OCT: model of OCT device, manufacturer and any technical characteristics (e.g. software
analyses). TISA, ARA, AOD 500 microns and 750 microns for each parameter
Follow up Numbers of participants lost to follow-up or who had uninterpretable test results
Notes Source of funding, anything else of relevance
Assessment of methodological quality
Two review authors will independently assess each included study
for risk of bias using theQUADAS2 tool to assess the susceptibility
to bias of the included studies, based on guidance presented in
Table 1 (Whiting 2011). We will assess each study and judge each
bias criterion to be at ’high’, ’low’ or ’unclear’ risk of bias (lack of
information or uncertainty over the potential for bias). Concerns
regarding applicability will be rated as ’high’, ’low’ or ’unclear’
concerns.
Statistical analysis and data synthesis
We aim to extract and analyse the data available at fixed thresholds
for each index test, in order to ease the interpretability of our
summary measures of accuracy. Our preferred thresholds will be:
• flashlight/pen torch/oblique handlight technique: grades 1
and 2;
• LACD using the van Herick technique: van Herick grades 1
and 2 (percentages will be converted to grades as appropriate);
• SPAC: categorical grading of suspect angle closure or
potential angle closure, as provided by the device.
As there is no current consensus regarding thresholds for Pentacam
Scheimpflugphotography andAS-OCT,wewill extract these data,
if available, from the included studies.
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If we identify sufficient studies providing data at fixed thresholds
for each test, we will fit a bivariate model using the METADAS
macro in SAS. If fixed thresholds are sparsely or incompletely re-
ported in studies we will fit hierarchical summary receiver oper-
ating characteristic (HSROC) curve models using the same soft-
ware. For comparisons between index tests, we will use a covari-
ate coding for each test in the bivariate or HSROC model. If the
HSROC model is appropriate, we will assume the same shape for
a summary receiver operating characteristic (sROC) curve for all
index tests and we will compare them using relative diagnostic
odds ratio (DOR). We will also report estimates of test accuracy,
such as sensitivity values at 90% and 95% specificity, which are
useful measures of the performance screening test.
We will assess and compare the accuracy of different index tests
using all available studies, thus allowing for indirect comparisons.
As Takwoingi 2013 showed that direct comparisons conducted
within each study are more reliable than indirect comparisons,
we will also present such within-study comparisons graphically in
ROC plots. We will plot data points and join the two estimates
(one for each test) from each study by a line to show the difference
in accuracy between tests. If a sufficient number of such paired
studies are available, we will pool them in bivariate or HSROC
meta-analyses, as appropriate, and test their relative accuracy with
a covariate coding for each test using themethods described above.
Since narrow angles are often bilateral, this complication may re-
sult in unit of analysis issues. We will include studies that evalu-
ated only one eye of each participant or, in participants with two
affected eyes, studies that randomly selected only one eye.We will
also include studies that included both eyes in our review, but we
will acknowledge the unit of analysis issue when formulating our
conclusions (i.e. acknowledging the overestimate of the precision
in accuracy).
Investigations of heterogeneity
We will initially investigate any heterogeneity in sensitivity and
specificity through the visual inspection of forest plots and the
degree to which individual study results lie close to the summary
ROCcurve. For diagnostic testswith a sufficient number of eligible
studies, we plan to formally explore heterogeneity by using the
following study-level covariates:
• study design (e.g. single-gate and two-gate designs);
• diagnostic reference thresholds (gonioscopy grading (e.g.
number of quadrants occluded));
• characteristics of the study population (e.g. high versus low
prevalence, ethnicity).
Sensitivity analyses
If we identify sufficient studies, we will perform a sensitivity anal-
ysis to assess the impact of risk of bias on test accuracy by repeating
the analysis after removing studies at high risk of bias.
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A D D I T I O N A L T A B L E S
Table 1. Guidance for QUADAS 2 assessment of risk of bias
DOMAIN LOW HIGH UNCLEAR
PARTICIPANT
SELECTION
Describemethods of participant selection; describe includedparticipants (prior testing, presentation,
intended use of index test and setting)
Was a consecutive or ran-
dom sample of participants
enrolled?
Consecutive sampling or ran-
dom sampling of people accord-
ing to inclusion criteria
Non-consecutive cohort of re-
ferrals (from primary care) or
(in screening setting) sampling
based on volunteering or refer-
ral
Unclear whether consecutive or
random sampling used
Was a case-control design
avoided?
Noselective recruitment of peo-
ple with or without narrow an-
gles, or nested case-control de-
signs (systematically and ran-
domly selected from a defined
population cohort)
Selection of either cases or con-
trols in a predetermined, non-
random fashion; or enrichment
of the cases from a selected pop-
ulation
Unclear selection mechanism
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Table 1. Guidance for QUADAS 2 assessment of risk of bias (Continued)
Did the study avoid inappro-
priate exclusions?
Exclusions are detailed and felt
to be appropriate (e.g. people
with corneal opacities, known
ocular malformation or disease
causing bulbar derangement)
Inappropriate exclusions are re-
ported (e.g. of people with bor-
derline index test results)
Exclusions are not detailed
(pending contact with study au-
thors)
Risk of bias: could the selec-
tion of participants have in-
troduced bias?
All signalling questions = ‘Yes’ Any signalling question = ‘No’ Unclear
Concerns regarding applica-
bility: are there concerns that
the included participants do
not match the review ques-
tion?
Inclusion of participants with-
out a previous diagnosis of a
narrow angle
Inclusion of participants with a
previous diagnosis of a narrow
angle
Unclear inclusion criteria
INDEX TEST Describe the index test and how it was conducted and interpreted
Were the index test results in-
terpreted without knowledge
of the results of the reference
standard?
Test performed “blinded” or
“independently and without
knowledge of” reference stan-
dard results are sufficient and
full details of the blinding pro-
cedure are not required; or clear
temporal pattern to the order of
testing that precludes the need
for formal blinding
Reference standard results were
available to those who con-
ducted or interpreted the index
tests
Unclear whether results are in-
terpreted independently
If a threshold was used, was it
prespecified?
The study authors declare that
the selected cut-off used to di-
chotomise data was specified a
priori; or a protocol is available
with this information
A study is classified at higher
risk of bias if the authors define
the optimal cut-off post hoc,
based on their own study data
No information on preselection
of index test cut-off values
Risk of bias: could the con-
duct or interpretation of the
index test have introduced
bias?
All signalling questions = ‘Yes’ Any signalling question = ‘No’ Unclear
Concerns regarding applica-
bility: are there concerns that
the index test, its conduct or
interpretation differ from the
review question?
Tests used and testing proce-
dure clearly reported and tests
executed by personnel with suf-
ficient training
Tests used are not validated
or study personnel was insuffi-
ciently trained
Unclear execution of the tests or
unclear study personnel profile,
background and training
REFERENCE STANDARD Describe the reference standard and how it was conducted and interpreted
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Table 1. Guidance for QUADAS 2 assessment of risk of bias (Continued)
Is the reference standard
likely to correctly classify the
target condition?
Not applicable. Score ‘Yes’ for all studies
Were the reference standard
results interpreted without
knowledge of the results of
the index test?
Reference standard performed
“blinded” or “independently
and without knowledge of” in-
dex test results are sufficient and
full details of the blinding pro-
cedure are not required; or clear
temporal pattern to the order of
testing that precludes the need
for formal blinding
Index test results were available
to those who conducted the ref-
erence standard
Unclearwhether resultswere in-
terpreted independently
Risk of bias: could the refer-
ence standard, its conduct or
its interpretation have intro-
duced bias?
All signalling questions = ‘Yes’ Any signalling question = ‘No’ Unclear
Concerns regarding applica-
bility: are there concerns that
the target condition as de-
fined by the reference stan-
dard does not match the re-
view question?
Not applicable. Score ‘Yes’ for all studies
FLOW AND TIMING Describe any participants who did not receive the index test(s) or reference standard, or either, or
who were excluded from the 2 x 2 table (refer to study flow diagram); describe the time interval and
any interventions between index test(s) and reference standard
Was there an appropriate in-
terval between index test(s)
and reference standard?
Nomore than three months be-
tween index and reference test
execution
More than three months be-
tween index and reference test
execution
Unclear whether test results
were executed within three
months
Did all participants receive a
reference standard?
All participants receiving the in-
dex test were verified with the
reference standard
Not all participants receiving
the index test were verified with
the reference standard
Unclearwhether all participants
receiving the index test were
verified with the reference stan-
dard
Did all participants receive
the same reference standard?
Not applicable. Score ‘Yes’ for all studies
Were all participants included
in the analysis?
The number of participants in-
cluded in the study match the
number in analysis
The number of participants in-
cluded in the study does not
match the number in analysis
Insufficient information
on whether the number of par-
ticipants included in the study
matches the number in analysis
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Table 1. Guidance for QUADAS 2 assessment of risk of bias (Continued)
Risk of bias: could the partici-
pants’ flow through the study
have introduced bias?
All signalling questions = ‘Yes’ Any signalling question = ‘No’ Unclear
A P P E N D I C E S
Appendix 1. The Cochrane Library search strategy
#1 MeSH descriptor: [Glaucoma, Angle-Closure] this term only
#2 angle* near/3 (occlud* or narrow* or width or close* or closure)
#3 glaucoma* near/3 (occlud* or narrow* or width or close* or closure)
#4 PAC or PACS or PACG or ACG
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Anterior Chamber] this term only
#7 MeSH descriptor: [Anterior Eye Segment] this term only
#8 anterior near/2 (chamber or segment)
#9 ACD or ACA
#10 #6 or #7 or #8 or #9
#11 MeSH descriptor: [Glaucoma] explode all trees
#12 #10 and #11
#13 #5 or #12
#14 MeSH descriptor: [Diagnostic Techniques, Ophthalmological] explode all trees
#15 flashlight* or torch
#16 MeSH descriptor: [Slit Lamp] this term only
#17 MeSH descriptor: [Slit Lamp Microscopy] this term only
#18 slit near/2 (lamp or beam)
#19 biomicroscope
#20 anterior chamber depth*
#21 Anterior chamber volume
#22 lens volume
#23 ACD or LACD or SPAC or ACV
#24 Herick
#25 Scheimpflug or Pentacam or Sirius or Galilei
#26 MeSH descriptor: [Tomography, Optical Coherence] explode all trees
#27 optical coherence tomograph*
#28 AS-OCT or Visanti
#29 anterior segment imag*
#30 angle recess area
#31 angle opening distance
#32 (angle or area*) near/2 trabec* near/2 iris
#33 AOD or TISA
#34 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #33
#35 #13 and #34
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Appendix 2. MEDLINE Ovid search strategy
1. Glaucoma, Angle-Closure/
2. (angle$ adj3 (occlud$ or narrow$ or width or close$ or closure)).tw.
3. (glaucoma$ adj3 (occlud$ or narrow$ or width or close$ or closure)).tw.
4. (PAC or PACS or PACG or ACG).tw.
5. or/1-4
6. Anterior Chamber/
7. Anterior Eye Segment/
8. (anterior adj2 (chamber or segment)).tw.
9. (ACD or ACA).tw.
10. or/6-9
11. exp Glaucoma/
12. 10 and 11
13. 5 or 12
14. Diagnostic Techniques, Ophthalmological/
15. (flashlight$ or torch).tw.
16. Slit Lamp/
17. Slit Lamp Microscopy/
18. (slit adj2 (lamp or beam)).tw.
19. biomicroscope.tw.
20. anterior chamber depth$.tw.
21. (ACD or LACD or SPAC).tw.
22. Herick.tw.
23. (Scheimpflug or Pentacam or Sirius or Galilei).tw.
24. Tomography, Optical Coherence/
25. optical$ coherence tomograph$.tw.
26. (AS-OCT or Visanti).tw.
27. anterior segment imag$.tw.
28. angle recess area.tw.
29. angle opening distance.tw.
30. ((angle or area$) adj2 trabec$ adj2 iris).tw.
31. (AOD or TISA).tw.
32. or/14-31
33. 13 and 32
34. exp case report/
35. (case adj1 (study or report$)).tw.
36. 34 or 35
37. 33 not 36
Appendix 3. Embase Ovid search strategy
1. closed angle glaucoma/ or glaucomatous optic neuropathy/ or neovascular glaucoma/ or secondary glaucoma/
2. (angle$ adj3 (occlud$ or narrow$ or width or close$ or closure)).tw.
3. (glaucoma$ adj3 (occlud$ or narrow$ or width or close$ or closure)).tw.
4. (PAC or PACS or PACG or ACG).tw.
5. or/1-4
6. anterior eye chamber/
7. anterior eye segment/
8. (anterior adj2 (chamber or segment)).tw.
9. (ACD or ACA).tw.
10. or/6-9
11. exp glaucoma/
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12. 10 and 11
13. 5 or 12
14. (flashlight or torch).tw.
15. slit lamp/
16. (slit adj2 (lamp or beam)).tw.
17. biomicroscope.tw.
18. anterior eye chamber angle/
19. anterior eye chamber depth/
20. anterior chamber depth$.tw.
21. Anterior chamber volume.tw.
22. lens volume.tw.
23. (ACD or LACD or SPAC or ACV).tw.
24. Herick.tw.
25. ophthalmic camera/
26. (Scheimpflug or Pentacam or Sirius or Galilei).tw.
27. optical coherence tomography/
28. optical$ coherence tomograph$.tw.
29. (AS-OCT or Visanti).tw.
30. anterior segment imag$.tw.
31. angle recess area.tw.
32. angle opening distance.tw.
33. ((angle or area$) adj2 trabec$ adj2 iris).tw.
34. (AOD or TISA).tw.
35. or/14-34
36. 13 and 35
Appendix 4. BIOSIS search strategy
#29 #28 AND #27
#28 TS= (human or humans)
#27 #26 AND #10
#26 #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11
#25 TS=(AOD or TISA)
#24 TS= ((angle or area*) NEAR/2 trabec* NEAR/2 iris)
#23 TS= (angle opening distance)
#22 TS= (angle recess area)
#21 TS= (anterior segment imag*)
#20 TS = (AS-OCT or Visanti)
#19 TS= (optical* coherence tomograph*)
#18 TS= (Herick or Scheimpflug or Pentacam or Sirius or Galilei)
#17 TS= (ACD or LACD or SPAC or ACV)
#16 TS= (lens volume)
#15 TS= (Anterior chamber volume)
#14 TS= (anterior chamber depth)
#13 TS=biomicroscope
#12 TS=(slit NEAR/2 (lamp or beam))
#11 TS= (flashlight* or torch)
#10 #9 OR #4
#9 #8 AND #7
#8 TS= Glaucoma
#7 #6 OR #5
#6 TS= (ACD or ACA)
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#5 TS= (anterior NEAR/2 (chamber or segment))
#4 #3 OR #2 OR #1
#3 TS= (PAC or PACS or PACG or ACG)
#2 TS= (glaucoma* NEAR/3 (occlud* or narrow* or width or close* or closure))
#1 TS = (angle* NEAR/3 (occlud* or narrow* or width or close* or closure))
Appendix 5. OpenGrey search strategy
(angle closure glaucoma OR PAC OR PACS OR PACG OR ACG) AND (flashlight OR torch OR Slit Lamp OR biomicroscope OR
anterior chamber depth OR ACD OR LACD OR SPAC OR Scheimpflug OR Pentacam OR Optical Coherence Tomography OR
Visanti)
Appendix 6. ARIF search strategy
(angle closure glaucoma OR PAC OR PACS OR PACG OR ACG) (All indexed fields) AND (flashlight OR torch OR Slit Lamp OR
biomicroscope OR anterior chamber depth OR ACD OR LACD OR SPAC OR Scheimpflug OR Pentacam OR Optical Coherence
Tomography OR Visanti) (All indexed fields)
Appendix 7. ISRCTN search strategy
(angle closure glaucoma OR PAC OR PACS OR PACG OR ACG) AND (flashlight OR torch OR Slit Lamp OR biomicroscope OR
anterior chamber depth OR ACD OR LACD OR SPAC OR Scheimpflug OR Pentacam OR Optical Coherence Tomography OR
Visanti)
Appendix 8. ClinicalTrials.gov search strategy
(angle closure glaucoma OR PAC OR PACS OR PACG OR ACG) AND (flashlight OR torch OR Slit Lamp OR biomicroscope OR
anterior chamber depth OR ACD OR LACD OR SPAC OR Scheimpflug OR Pentacam OR Optical Coherence Tomography OR
Visanti)
Appendix 9. ICTRP search strategy
angle closure glaucoma OR PAC OR PACS OR PACG OR ACG = Condition AND flashlight OR torch OR Slit Lamp OR biomi-
croscope OR anterior chamber depth OR ACD OR LACD OR SPAC OR Scheimpflug OR Pentacam OR Optical Coherence To-
mography OR Visanti = Intervention
Appendix 10. List of abbreviations
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PACS
PAC
PACG
IOP
ITC
PAS
ACA
ACD
LACD
ACV
SPAC
AS-OCT
TISA
ARA
AOD
Primary angle closure suspect
Primary angle closure
Primary angle closure glaucoma
Intraocular pressure
Irido-trabecular contact
Peripheral anterior synechiae
Anterior chamber angle
Anterior chamber depth
Limbal anterior chamber depth
Anterior chamber volume
Scanning peripheral anterior chamber analysis
Anterior segment ocular coherence tomography
Trabeculo-iris space area
Angle recess area
Angle opening distance
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